# CMOEP in the Treatment of Untreated Peripheral T-cell Lymphoma

> **NCT05458180** · PHASE1 · UNKNOWN · sponsor: **Tianjin Medical University Cancer Institute and Hospital** · enrollment: 18 (estimated)

## Conditions studied

- Peripheral T-cell Lymphoma

## Interventions

- **DRUG:** Lposomal mitoxantrone hydrochloride,Cyclophosphamide,Vincristine,Etoposide and Prednisone(CMOEP)

## Key facts

- **NCT ID:** NCT05458180
- **Lead sponsor:** Tianjin Medical University Cancer Institute and Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-07-07
- **Primary completion:** 2024-12-15
- **Final completion:** 2025-04-15
- **Target enrollment:** 18 (ESTIMATED)
- **Last updated:** 2022-07-14

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05458180

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05458180, "CMOEP in the Treatment of Untreated Peripheral T-cell Lymphoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05458180. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*